FDA Extends Comment Period for Draft Guidance on In Vitro Diagnostic Multivariate Index Assays

Summary

The FDA is extending the comment period for its draft guidance on In Vitro Diagnostic Multivariate Index Assays, allowing more time for industry, clinical laboratories, and FDA staff to review and submit comments.